Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancer

  1. Roca, J.-M.
  2. Alonso, V.
  3. Pericay, C.
  4. Escudero, P.
  5. Salud, A.
  6. Losa, F.
  7. López, L.-J.
  8. Guasch, I.
  9. Méndez, M.
  10. Quintero-Aldana, G.
  11. Grande, C.
  12. Vicente, P.
  13. Arrivi, A.
  14. Martin, C.
  15. Moreno, I.
  16. García, P.
  17. Antón, I.
  18. Constenla, M.
  19. Yubero, A.
  20. Cirera, L.
Journal:
Chemotherapy

ISSN: 0009-3157

Year of publication: 2010

Volume: 56

Issue: 2

Pages: 142-146

Type: Article

DOI: 10.1159/000313527 GOOGLE SCHOLAR

Sustainable development goals